Tier 3 Drug Shortages
Tier 3 drug shortages are those that have the greatest potential impact on Canada's drug supply and health care system. Impact is based on low availability of alternative supplies, ingredients or therapies. The Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders, makes recommendations on the tier assignment of drug shortages. The TAC assessment includes:
- a review of the information gathered on the shortage issue, and
- a thorough discussion on its potential impact and next steps.
Below are the newest and most recently updated active ingredients that have been designated as Tier 3 shortages. Click on the active ingredient to see a list of the associated Tier 3 drug shortage and/or discontinuation reports.
Active Ingredient
20 active ingredients found
ALDESLEUKIN
powder for solution |
Alprostadil Sterile Solution
solution |
ANAGRELIDE
capsule |
Apomorphine Hydrochloride
solution |
Apomorphine Hydrochloride
film, soluble |
ASPARAGINASE - ERWINASE
powder for solution |
CALCITONIN
solution |
CHOLESTYRAMINE RESIN
powder for suspension |
DEXTROSE INJECTION
solution |
DOCETAXEL INJECTION
solution |
Eluxadoline
tablet |
GLUCAGON
powder for solution |
IDARUBICIN HYDROCHLORIDE
solution |
LITHIUM CARBONATE
capsule |
LITHIUM CARBONATE
tablet (extended-release) |
Methotrexate
solution |
Pantoprazole Sodium for Injection
powder for solution |
PEGASPARGASE
solution |
peginterferon alfa-2A injection
solution |
PROPARACAINE HYDROCHLORIDE
drops |